Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection.

Basu D, Kraft CS, Murphy MK, Campbell PJ, Yu T, Hraber PT, Irene C, Pinter A, Chomba E, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E.

Retrovirology. 2012 Sep 20;9:76. doi: 10.1186/1742-4690-9-76.

2.

Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response.

Wagner GA, Landais E, Caballero G, Phung P, Kosakovsky Pond SL, Poignard P, Richman DD, Little SJ, Smith DM.

J Virol. 2017 Aug 10;91(17). pii: e00475-17. doi: 10.1128/JVI.00475-17. Print 2017 Sep 1.

PMID:
28615205
3.

HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response.

Cortez V, Odem-Davis K, McClelland RS, Jaoko W, Overbaugh J.

PLoS Pathog. 2012;8(3):e1002611. doi: 10.1371/journal.ppat.1002611. Epub 2012 Mar 29.

4.

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.

5.

Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.

Blish CA, Dogan OC, Derby NR, Nguyen MA, Chohan B, Richardson BA, Overbaugh J.

J Virol. 2008 Dec;82(24):12094-103. doi: 10.1128/JVI.01730-08. Epub 2008 Oct 8.

6.

Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection.

Basu D, Xiao P, Ende Z, Bere A, Britt WJ, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E.

Virology. 2014 Aug;462-463:295-8. doi: 10.1016/j.virol.2014.06.016. Epub 2014 Jul 5.

7.

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L; CAPRISA 002 Study; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

PLoS Pathog. 2009 Sep;5(9):e1000598. doi: 10.1371/journal.ppat.1000598. Epub 2009 Sep 18.

8.

Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA.

PLoS Pathog. 2013 Feb;9(2):e1003173. doi: 10.1371/journal.ppat.1003173. Epub 2013 Feb 28.

9.

The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection.

Cortez V, Wang B, Dingens A, Chen MM, Ronen K, Georgiev IS, McClelland RS, Overbaugh J.

PLoS Pathog. 2015 Jul 9;11(7):e1004973. doi: 10.1371/journal.ppat.1004973. eCollection 2015 Jul.

10.

Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection.

Forthal DN, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, Blish C, Overbaugh J.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):31-3. doi: 10.1097/QAI.0b013e3182874d41.

11.

Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.

Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H, Greene KM, McCutchan F, Williamson C, Kim JH, Tovanabutra S, Hahn BH, Swanstrom R, Thomson MM, Gao F, Harris L, Giorgi E, Hengartner N, Bhattacharya T, Mascola JR, Montefiori DC.

J Virol. 2014 Nov;88(21):12623-43. doi: 10.1128/JVI.01705-14. Epub 2014 Aug 20.

12.

Contrasting antibody responses to intrasubtype superinfection with CRF02_AG.

Courtney CR, Mayr L, Nanfack AJ, Banin AN, Tuen M, Pan R, Jiang X, Kong XP, Kirkpatrick AR, Bruno D, Martens CA, Sykora L, Porcella SF, Redd AD, Quinn TC, Nyambi PN, Dürr R.

PLoS One. 2017 Mar 13;12(3):e0173705. doi: 10.1371/journal.pone.0173705. eCollection 2017.

13.

Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.

Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, Chen X, Hwang KK, Montefiori DC, Liao HX, Hraber P, Fischer W, Li H, Wang S, Sterrett S, Keele BF, Ganusov VV, Perelson AS, Korber BT, Georgiev I, McLellan JS, Pavlicek JW, Gao F, Haynes BF, Hahn BH, Kwong PD, Shaw GM.

PLoS Pathog. 2012;8(5):e1002721. doi: 10.1371/journal.ppat.1002721. Epub 2012 May 31.

14.

Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.

Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, Abdool Karim SS, Shapiro L, Williamson C, Kwong PD, Mascola JR, Morris L, Moore PL.

Nat Med. 2015 Nov;21(11):1332-6. doi: 10.1038/nm.3963. Epub 2015 Oct 12.

15.

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Archary D, Rong R, Gordon ML, Boliar S, Madiga M, Gray ES, Dugast AS, Hermanus T, Goulder PJ, Coovadia HM, Werner L, Morris L, Alter G, Derdeyn CA, Ndung'u T.

Virology. 2012 Nov 25;433(2):410-20. doi: 10.1016/j.virol.2012.08.033. Epub 2012 Sep 18.

16.

Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.

Smith DM, Strain MC, Frost SD, Pillai SK, Wong JK, Wrin T, Liu Y, Petropolous CJ, Daar ES, Little SJ, Richman DD.

Virology. 2006 Nov 10;355(1):1-5. Epub 2006 Sep 7.

17.

Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.

Smith SA, Burton SL, Kilembe W, Lakhi S, Karita E, Price M, Allen S, Hunter E, Derdeyn CA.

PLoS Pathog. 2016 Nov 16;12(11):e1005989. doi: 10.1371/journal.ppat.1005989. eCollection 2016 Nov.

18.

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L; CAPRISA 002 Study.

J Virol. 2011 Apr;85(7):3128-41. doi: 10.1128/JVI.02658-10. Epub 2011 Jan 26.

19.

HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads.

Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J.

PLoS Pathog. 2012;8(6):e1002739. doi: 10.1371/journal.ppat.1002739. Epub 2012 Jun 14.

20.

epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.

Tang H, Robinson JE, Gnanakaran S, Li M, Rosenberg ES, Perez LG, Haynes BF, Liao HX, Labranche CC, Korber BT, Montefiori DC.

J Virol. 2011 Sep;85(18):9286-99. doi: 10.1128/JVI.02286-10. Epub 2011 Jul 6.

Supplemental Content

Support Center